Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial
- Author:
Ji-Jung JUNG
1
;
Jong-Ho CHEUN
;
Soo-Yeon KIM
;
Jiwon KOH
;
Jai Min RYU
;
Tae-Kyung YOO
;
Hee-Chul SHIN
;
Sung Gwe AHN
;
Seho PARK
;
Woosung LIM
;
Sang-Eun NAM
;
Min Ho PARK
;
Ku Sang KIM
;
Taewoo KANG
;
Jeeyeon LEE
;
Hyun Jo YOUN
;
Yoo Seok KIM
;
Chang Ik YOON
;
Hong-Kyu KIM
;
Hyeong-Gon MOON
;
Wonshik HAN
;
Nariya CHO
;
Min Kyoon KIM
;
Han-Byoel LEE
Author Information
- Publication Type:Study Protocol
- From:Journal of Breast Cancer 2024;27(1):61-71
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Purpose:Advances in chemotherapeutic and targeted agents have increased pathologic complete response (pCR) rates after neoadjuvant systemic therapy (NST). Vacuum-assisted biopsy (VAB) has been suggested to accurately evaluate pCR. This study aims to confirm the non-inferiority of the 5-year disease-free survival of patients who omitted breast surgery when predicted to have a pCR based on breast magnetic resonance imaging (MRI) and VAB after NST, compared with patients with a pCR who had undergone breast surgery in previous studies.
Methods:The Omission of breast surgery for PredicTed pCR patients wIth MRI and vacuumassisted bIopsy in breaST cancer after neoadjuvant systemic therapy (OPTIMIST) trial is a prospective, multicenter, single-arm, non-inferiority study enrolling in 17 tertiary care hospitals in the Republic of Korea. Eligible patients must have a clip marker placed in the tumor and meet the MRI criteria suggesting complete clinical response (post-NST MRI size ≤ 1 cm and lesion-to-background signal enhancement ratio ≤ 1.6) after NST. Patients will undergo VAB, and breast surgery will be omitted for those with no residual tumor. Axillary surgery can also be omitted if the patient was clinically node-negative before and after NST and met the stringent criteria of MRI size ≤ 0.5 cm. Survival and efficacy outcomes are evaluated over five years.Discussion: This study seeks to establish evidence for the safe omission of breast surgery in exceptional responders to NST while minimizing patient burden. The trial will address concerns about potential undertreatment due to false-negative results and recurrence as well as improved patient-reported quality of life issues from the omission of surgery. Successful completion of this trial may reshape clinical practice for certain breast cancer subtypes and lead to a safe and less invasive approach for selected patients.
